[10] Lipo-B (MIC) injections are generally well tolerated in most individuals
REDEFINE 1 (Garvey et al., NEJM 2025) is the only Phase 3 trial of an amylin + incretin co-administered combination, pairing cagrilintide 2.4 mg with semaglutide 2.4 mg
i) FORCE MAJEURE: The Company is not liable for any failure to perform due to causes beyond its reasonable control including, but not limited to, acts of God, acts of civil authorities, acts of military authorities, riots, embargoes, acts of nature and natural disasters, and other acts which may be due to unforeseen circumstances
By removing the need for injections, capsules avoid needle-related discomfort and reduce the risk of injection-associated complications, making them suitable for those research subjects with needle sensitivity
Moreover, Li et al